“Swing Factors” Will Heavily Influence GSK Growth In ’08, Chief Exec Garnier Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcome of a plan to jumpstart sales of Avandia and FDA approval of Cervarix are two key issues that will impact GSK in the new year.